Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Some Drug Trials Resume after Declines During Pandemic

Michael Erman & Carl O'Donnell  |  

(Reuters)—Pharmaceutical companies have ramped up clinical trials in the past month, rebounding from a steep decline in activity following the start of the COVID-19 outbreak, though activity remains below pre-pandemic levels, according to new research shareS with Reuters.

The research, which was prepared by clinical trial consulting firm Medidata, shows that new subjects entered trials globally in June at a 30% lower rate than they did before the pandemic. But that is significantly higher than the roughly 70% decline in new subject starts in April.

ADVERTISEMENT
SCROLL TO CONTINUE

(Reporting by Carl O’Donnell; Editing by Leslie Adler)

Related Articles

    Vax Hesitancy? Myths & Facts for Patients

    Although more than 189,300,000 eligible Americans are fully vaccinated against SARS-CoV-2 as of Oct. 18, 2021, vaccine hesitancy persists.1 The U.S. Centers for Disease Control and Prevention (CDC), citing data from the U.S. Census Bureau’s Household Pulse Survey collected between May 26 and June 7, 2021, reports that in some U.S. counties—particularly in the Southeast…

    Rheumatology in a COVID & Post-COVID World

    Jane’s* hands and wrists had been swollen and painful for about eight weeks. Lab findings in the ambulatory consult that came to our office revealed a cyclic citrullinated peptide antibody count >250 u/mL. We all know where this story goes, including how important the early treatment window is. Our clinic reviews all consults and tries…